EGFR and non-small cell lung carcinoma: EGFR tyrosine-kinase inhibitors (gefitinib, erlotinib) are considered the standard first-line treatment for patients with EGFR mutations and therefore it is recommended that screening for EGFR mutations should be a part of the routine clinical practice for NSCLC patients [20,23].